XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer

DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5)...

Full description

Saved in:
Bibliographic Details
Published in:Acta biochimica et biophysica Sinica 2009-05, Vol.41 (5), p.429-435
Main Authors: Feng, Jifeng, Sun, Xinchen, Sun, Ning, Qin, Shukui, Li, Fan, Cheng, Hongyan, Chen, Baoan, Cao, YuanDong, Ma, Jun, Cheng, Lu, Lu, Zuhong, Ji, Jiazhong, Zhou, Yingfeng
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Cisplatin - administration & dosage
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
DNA-Binding Proteins - genetics
Docetaxel
Endonucleases - genetics
Female
Gene Frequency
Genotype
Humans
Logistic Models
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Middle Aged
Nuclear Proteins - genetics
Paclitaxel - administration & dosage
Polymorphism, Single Nucleotide
Taxoids - administration & dosage
Transcription Factors - genetics
Treatment Outcome
Vinblastine - administration & dosage
Vinblastine - analogs & derivatives
Vinorelbine
Xeroderma Pigmentosum Group A Protein - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A → G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.
ISSN:1672-9145
1745-7270
DOI:10.1093/abbs/gmp027